Blood Res.  2022 Apr;57(S1):S44-S48. 10.5045/br.2022.2022025.

Challenging issues in the management of cancer-associated venous thromboembolism

• Yhim HY

• KMID: 2529306
• DOI: http://doi.org/10.5045/br.2022.2022025

Abstract

Venous thromboembolism (VTE) is a common complication among patients with cancer and is associated with delays in underlying cancer treatment and increases in morbidity and mortality. Acute and long-term treatments with low-molecular-weight-heparin (LMWH) have been recommended as a standard of care for patients with cancer with VTE for the past 20 years. Direct oral anticoagulants (DOACs) have recently emerged as a new therapeutic modality for cancer-associated VTE because of the convenience of oral administration and rapid onset of action. Our knowledge regarding DOACs for cancer-associated VTD has expanded in recent years. Thus, this study aimed to review recent major pivotal trials comparing DOACs with LMWH for managing cancer-associated VTE. Moreover, a recently updated understanding of DOACs in the treatment of cancer-associated VTE in specific challenging situations is presented.

Keyword

Cancer; Direct oral anticoagulant; Venous thromboembolism